Ungerechts et al., 2017 - Google Patents
Virotherapy research in Germany: from engineering to translationUngerechts et al., 2017
View PDF- Document ID
- 8769326282181341042
- Author
- Ungerechts G
- Engeland C
- Buchholz C
- Eberle J
- Fechner H
- Geletneky K
- Holm P
- Kreppel F
- Kühnel F
- Lang K
- Leber M
- Marchini A
- Moehler M
- Mühlebach M
- Rommelaere J
- Springfeld C
- Lauer U
- Nettelbeck D
- Publication year
- Publication venue
- Human gene therapy
External Links
Snippet
Virotherapy is a unique modality for the treatment of cancer with oncolytic viruses (OVs) that selectively infect and lyse tumor cells, spread within tumors, and activate anti-tumor immunity. Various viruses are being developed as OVs preclinically and clinically, several of …
- 238000000316 virotherapy 0 title abstract description 45
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
- C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mondal et al. | Recent advances of oncolytic virus in cancer therapy | |
| Howells et al. | Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer | |
| Ungerechts et al. | Virotherapy research in Germany: from engineering to translation | |
| Vile et al. | Cancer gene therapy: hard lessons and new courses | |
| Power et al. | Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer | |
| Lundstrom | New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| Atherton et al. | Evolution of oncolytic viruses: novel strategies for cancer treatment | |
| Asad et al. | Viral gene therapy for breast cancer: progress and challenges | |
| Yaghchi et al. | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer | |
| Brenner et al. | Is cancer gene therapy an empty suit? | |
| Zaoui et al. | Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus | |
| Jayawardena et al. | Virus–receptor interactions and virus neutralization: insights for oncolytic virus development | |
| Kaufmann et al. | Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus | |
| Gonzalez-Aseguinolaza et al. | Gene therapy of liver diseases: A 2011 perspective | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| Touchefeu et al. | Gene therapy, recent developments and future prospects in gastrointestinal oncology | |
| McCrudden et al. | Current status of gene therapy for breast cancer: progress and challenges | |
| Cody et al. | Promising oncolytic agents for metastatic breast cancer treatment | |
| Ajina et al. | Synergistic combination of oncolytic virotherapy with CAR T-cell therapy | |
| Vachani et al. | Gene therapy for mesothelioma and lung cancer | |
| Zhu et al. | Recent advances in oncolytic virus therapy for hepatocellular carcinoma | |
| Liu et al. | Advances in viral-vector systemic cytokine gene therapy against cancer | |
| Tenneti et al. | Exploring the role of oncolytic viruses in hepatobiliary cancers | |
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers |